Literature DB >> 3519464

Antibodies raised against rough mutants of Escherichia coli and Salmonella strains are opsonic only in the presence of complement.

R W Vreede, J H Marcelis, J Verhoef.   

Abstract

The opsonic capacity of antisera raised in rabbits against rough (R) mutants and smooth (S) parent strains of Escherichia coli and Salmonella typhimurium were studied. All specific antibodies in the antisera belonged to the immunoglobulin G (IgG) class. Radioactively labeled bacteria were preincubated in various dilutions of antisera, in which complement was inactivated. Fresh normal rabbit serum, as a standard complement source, was used in some experiments. After preincubation, washed bacteria were added to normal human neutrophils. Opsonization of R mutants for 5 min in 5% fresh normal rabbit serum resulted in effective phagocytosis; S strains needed at least a 30-min opsonization time or 20 to 50% serum. After incubation for 5 min in diluted, homologous antisera, phagocytosis of S strains was optimal, but preincubation of R mutants in diluted, homologous antisera did not lead to amelioration of phagocytosis compared with that of bacteria preincubated in buffer only. However, when fresh normal serum was added to homologous antisera, uptake of R mutants occurred at a faster rate than that of bacteria opsonized in fresh serum alone. Using six clinical isolates of members of the family Enterobacteriaceae, we found that, with or without complement, antisera raised against E. coli J5 or S. typhimurium Re had, with the exception of one strain, no opsonic activity for these strains. Thus, the protective effect of R antisera in gram-negative bacteremia, as shown by several investigators, is unlikely to be mediated through enhanced opsonization of invading bacteria by IgG antibodies directed against these R mutants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519464      PMCID: PMC260944          DOI: 10.1128/iai.52.3.892-896.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity.

Authors:  P Stevens; S N Huang; W D Welch; L S Young
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

2.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

3.  Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

Authors:  L S Young; P Stevens; J Ingram
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

4.  Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria.

Authors:  J Verhoef; P K Peterson; P G Quie
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

5.  Escherichia coli antibodies in opsonisation and protection against infection.

Authors:  W C van Dijk; H A Verbrugh; M E van Erne-van der Tol; R Peters; J Verhoef
Journal:  J Med Microbiol       Date:  1981-11       Impact factor: 2.472

6.  Relative opsonic and protective activities of antibodies against K1, O and lipid A antigens of Escherichia coli.

Authors:  W D Welch; W J Martin; P Stevens; L S Young
Journal:  Scand J Infect Dis       Date:  1979

7.  Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes.

Authors:  H A Verbrugh; R Peters; P K Peterson; J Verhoef
Journal:  J Clin Pathol       Date:  1978-06       Impact factor: 3.411

8.  Role of Escherichia coli K capsular antigens during complement activation, C3 fixation, and opsonization.

Authors:  W C Van Dijk; H A Verbrugh; M E van der Tol; R Peters; J Verhoef
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

9.  Protective capacity of antibodies against Escherichia coli and K antigens.

Authors:  B Kaijser; S Ahlstedt
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

10.  Studies on hemagglutination and hemolysis by escherichia coli antisera.

Authors:  E NETER; L F BERTRAM; D A ZAK; M R MURDOCK; C E ARBESMAN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

View more
  5 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

4.  Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans.

Authors:  Esther N Gondwe; Malcolm E Molyneux; Margaret Goodall; Stephen M Graham; Pietro Mastroeni; Mark T Drayson; Calman A MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

5.  Role of antibodies in the opsonization of Yersinia spp.

Authors:  R Tertti; E Eerola; K Granfors; R Lahesmaa-Rantala; K Pekkola-Heino; A Toivanen
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.